Piloting Movement-to-Music With Arm-based Sprint-Intensity Interval Training Among Children With Physical Disabilities

March 12, 2026 updated by: Byron Lai, University of Alabama at Birmingham

Improving Cardiorespiratory Fitness and Cardiometabolic Health Among Children With Physical Disabilities Through Movement-to-Music Telehealth With Arm-based Sprint-Intensity Interval Training

This study is investigating the potential effects of a high-intensity home-exercise program among children with cerebral palsy. The program includes rhythmic movements to music that are adapted for wheelchair uses and age-appropriate themes. This project has the potential to address a large knowledge gap in the extant literature, because there are no widely accessible, evidence-based, enjoyable, and age-appropriate modalities for improving cardiovascular fitness or cardiometabolic health among children with disabilities who have mobility disabilities.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

42

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alabama
      • Homewood, Alabama, United States, 35209
        • Wellness Health and Research Facility (WHARF)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 17 years (Child)

Accepts Healthy Volunteers

Yes

Description

We are recruiting 50 parent-child dyads. Childs are the participant undergoing the exercise intervention. Parents are required to support the safety and schedule of the child participant. Parents are considered participants due to their responsibilities.

Inclusion Criteria:

  • have a medical diagnosis of cerebral palsy, as determined by ICD-10 codes
  • aged 6-17 years old
  • a Gross Motor Function Classification System Level I-IV (as determined via participant screening, explained in the protocol section below)
  • medical clearance to participate in high-intensity exercise from a physician (using the attached medical screening form and explained in the intervention safety, monitoring, and response plan)
  • access to a Wi-Fi Internet connection in the home via mobile phone or tablet computer
  • a caregiver who will support and monitor the participant's safety during the intervention and manage the child's exercise schedule.

Exclusion Criteria:

  • physically active (defined as >150 minutes per week of self-reported moderate-to-vigorous intensity exercise in a typical week)
  • cannot use their arms for exercise
  • a Gross Motor Function Classification Level of V
  • complete blindness or deafness;
  • Any past history of a contraindication to exercise testing according to American College of Sports Medicine (ACSM) guidelines (Liguori and American College of Sports Medicine, 2020): significant change in the resting electrocardiogram suggesting significant ischemia, myocardial infarction, or other cardiac event, unstable angina, uncontrolled cardiac dysrhythmias causing symptoms or hemodynamic compromise, symptomatic severe aortic stenosis, uncontrolled symptomatic heart failure, pulmonary embolus or pulmonary infarction, myocarditis or pericarditis, aneurysm.
  • pregnant (due to radiation from a Dual Energy X-ray Absorptiometry [DEXA] scan)
  • has not been seen by a physician within the last year
  • uses a g-tube

Eligible caregivers will include parents or legal guardians of the child, who can commit sufficient time to support the child in their roles for the study and communicate in English. Caregivers who have complete blindness or deafness will be excluded from participation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Movement-to-Music
12 weeks of sprint-intensity interval training while following along with YouTube videos that include arm-based routines, with coaching through telecommunications. Participants are instructed to maintain their habitual diet and nutrition patterns
Maximal intensity exercises that use the arms.
No Intervention: Wait-list Control
12 weeks of maintaining habitual physical activity, diet, and nutrition patterns, until receiving 12 weeks of Movement-to-Music

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in pVO2
Time Frame: Week 0, Week 13
peak oxygen consumption (mL/kg-1/min-1) obtained from a graded exercise test on an arm ergometer. Data represents the child participant. Outcome measures were not collected for the parent participant.
Week 0, Week 13

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Body Weight
Time Frame: Week 0, Week 13
body weight in kg measured via DXA scan. Data represents the child participant. Outcome measures were not collected for the parent participant.
Week 0, Week 13
Changes in Total Body Fat
Time Frame: Week 0, Week 13
body fat in kg measured via DXA scan. Data represents the child participant. Outcome measures were not collected for the parent participant.
Week 0, Week 13
Changes in Total Lean Mass
Time Frame: Week 0, Week 13
lean mass in kg measured via DXA scan. Data represents the child participant. Outcome measures were not collected for the parent participant.
Week 0, Week 13
Changes in Lean Tissue Percentage
Time Frame: Week 0, Week 13
percentage of lean tissue per whole body weight. Data represents the child participant. Outcome measures were not collected for the parent participant.
Week 0, Week 13
Changes in Fat Tissue Percentage
Time Frame: Week 0, Week 13
percentage of fat tissue per whole body weight. Data represents the child participant. Outcome measures were not collected for the parent participant.
Week 0, Week 13
Changes in C-reactive Protein
Time Frame: Week 0, Week 13
hsCRP (mg/L) measured via dried blood spot test. Data represents the child participant. Outcome measures were not collected for the parent participant.
Week 0, Week 13
Changes in Hemoglobin A1C
Time Frame: Week 0, Week 13
HbA1C (mmol/mol) measured via dried blood spot test. Data represents the child participant. Outcome measures were not collected for the parent participant.
Week 0, Week 13
Changes in Fasting Insulin
Time Frame: Week 0, Week 13
Fasting Insulin (μIU/mL) measured via dried blood spot test. Data represents the child participant. Outcome measures were not collected for the parent participant.
Week 0, Week 13
Changes in Fasting Triglycerides
Time Frame: Week 0, Week 13
Fasting Triglycerides (mg/dL) measured via dried blood spot test. Data represents the child participant. Outcome measures were not collected for the parent participant.
Week 0, Week 13
Changes in Fasting High-density Lipoprotein
Time Frame: Week 0, Week 13
HDL cholesterol (mg/dL) measured via dried blood spot test. Data represents the child participant. Outcome measures were not collected for the parent participant.
Week 0, Week 13
Changes in Fasting Low-density Lipoprotein
Time Frame: Week 0, Week 13
LDL cholesterol (mg/dL) measured via dried blood spot test. Data represents the child participant. Outcome measures were not collected for the parent participant.
Week 0, Week 13
Changes in Systolic Blood Pressure
Time Frame: Week 0, Week 13
systolic blood pressure (mmHg) measured via blood pressure cuff. Data represents the child participant. Outcome measures were not collected for the parent participant.
Week 0, Week 13
Changes in Diastolic Blood Pressure
Time Frame: Week 0, Week 13
diastolic blood pressure (mmHg) measured via blood pressure cuff. Data represents the child participant. Outcome measures were not collected for the parent participant.
Week 0, Week 13

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adherence to the Exercise Prescription
Time Frame: Week 1 - 12
Percentage of sessions attended versus prescribed. Data represents the child participant. Outcome measures were not collected for the parent participant.
Week 1 - 12
Number of Participants With Adverse Events
Time Frame: Week 1 - 12
Any adverse event reported by participants (e.g., injury). Data represents the child participant. Outcome measures were not collected for the parent participant.
Week 1 - 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 29, 2023

Primary Completion (Actual)

November 1, 2025

Study Completion (Actual)

December 18, 2025

Study Registration Dates

First Submitted

November 2, 2022

First Submitted That Met QC Criteria

November 8, 2022

First Posted (Actual)

November 16, 2022

Study Record Updates

Last Update Posted (Actual)

April 2, 2026

Last Update Submitted That Met QC Criteria

March 12, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • IRB-300010372
  • 1R21HD109358-01A1 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified data will be submitted into the NICHD Data and Specimen Hub (DASH). Intellectual property and data generated under this project will be administered in accordance with both University and NIH policies, including the NIH Data Sharing Policy and Implementation Guidance under notice NOT-OD-03-032 (released February 26, 2003)

IPD Sharing Time Frame

Beginning 3 months after publication and ending 5 years after publication.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebral Palsy

Clinical Trials on Sprint-Intensity Interval Training with Telecoaching

Subscribe